LiveCount Assay:: Concomitant measurement of cytolytic activity and phenotypic characterisation of CD8+ T-cells by flow cytometry
LiveCount Assay:: Concomitant measurement of cytolytic activity and phenotypic characterisation of CD8+ T-cells by flow cytometry
复制标题
DOI：
10.1016/j.jim.2006.01.011
复制
发表时间：
2006-04-20
影响因子：
2.2
通讯作者：
Mahnke, Yolanda D.
中科院分区：
文献类型：
--
作者：
Devevre, Estelle;Romero, Pedro;Mahnke, Yolanda D.
肿瘤免疫学家努力开发有效的肿瘤疫苗和过继性转移疗法，以扩大体内肿瘤特异性和反应性效应t细胞的数量。为了评估各种策略的效率，需要对患者的特异性免疫反应进行纵向监测，提供定量和定性数据。特别是，由于肿瘤细胞的细胞溶解是肿瘤免疫治疗的最终目标，常规免疫监测方案需要包括对ag特异性细胞的细胞溶解效率的读出。我们建议将当前的免疫监测技术结合在一个高度敏感和可重复的多参数流式细胞术基础上的细胞毒性试验中，该试验已被优化为需要低数量的ag特异性t细胞。在脱颗粒t细胞表面同时检测到CD107a上调，说明了重新分析那些经历了裂解活性的t细胞的可能性。迄今为止，LiveCount Assay提供了唯一一种评估患者材料中低频ag特异性细胞毒性t淋巴细胞体外溶细胞活性的方法。(c) 2006 Elsevier B.V.版权所有
Tumour immunologists strive to develop efficient tumour vaccination and adoptive transfer therapies that enlarge the pool of tumour-specific and -reactive effector T-cells in vivo. To assess the efficiency of the various strategies, ex vivo assays are needed for the longitudinal monitoring of the patient's specific immune responses providing both quantitative and qualitative data. In particular, since tumour cell cytolysis is the end goal of tumour immunotherapy, routine immune monitoring protocols need to include a read-out for the cylolytic efficiency of Ag-specific cells. We propose to combine current immune monitoring techniques in a highly sensitive and reproducible multi-parametric flow cytometry based cytotoxicity assay that has been optimised to require low numbers of Ag-specific T-cells. The possibility of reanalysing those T-cells that have undergone lytic activity is illustrated by the concomitant detection of CD107a upregulation on the surface of degranulated T-cells. To date, the LiveCount Assay provides the only possibility of assessing the ex vivo cytolytic activity of low-frequency Ag-specific cytotoxic T-lymphocytes from patient material. (c) 2006 Elsevier B.V. All rights reserved.